Paul Nathan

7PUBLICATIONS
104CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Takami Sato, Marcus O Butler, Sophie Piperno-Neumann

|Sep 09, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.

Fiona Collinson, Kara-Louise Royle, Jayne Swain

|Nov 06, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

Naveen S Vasudev, Gemma Ainsworth, Sarah Brown

|Apr 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.

James Larkin, Michele Del Vecchio, Mario Mandalá

|Mar 27, 2023
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.

Sarah Howlett, Thomas J Carter, Heather M Shaw

|Mar 07, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.

Richard D Carvajal, Paul Nathan, Joseph J Sacco

Pageof 2

Frequent Collaborators

3 joint publications

Marcus O Butler

2 joint publications

Reinhard Dummer

2 joint publications

Mark R Middleton

2 joint publications

Ana M Arance Fernandez